These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23625649)

  • 1. Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study.
    Spagnuolo V; Travi G; Galli L; Cossarini F; Guffanti M; Gianotti N; Salpietro S; Lazzarin A; Castagna A
    Cancer; 2013 Aug; 119(15):2710-9. PubMed ID: 23625649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
    Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
    Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
    Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
    J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical cancer in patients infected with the human immunodeficiency virus.
    Leitao MM; White P; Cracchiolo B
    Cancer; 2008 Jun; 112(12):2683-9. PubMed ID: 18438877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study.
    Hoffmann C; Hentrich M; Gillor D; Behrens G; Jensen B; Stoehr A; Esser S; van Lunzen J; Krznaric I; Müller M; Oette M; Hensel M; Thoden J; Fätkenheuer G; Wyen C
    HIV Med; 2015 Apr; 16(4):261-4. PubMed ID: 25252101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.
    Gotti D; Danesi M; Calabresi A; Ferraresi A; Albini L; Donato F; Castelli F; Scalzini A; Quiros-Roldan E;
    AIDS Patient Care STDS; 2013 May; 27(5):259-65. PubMed ID: 23600703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
    Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection.
    Spina M; Carbone A; Vaccher E; Gloghini A; Talamini R; Cinelli R; Martellotta F; Tirelli U
    Clin Infect Dis; 2004 Jan; 38(1):142-4. PubMed ID: 14679461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
    Sharma A; Bajpai J; Raina V; Mohanti BK
    Indian J Cancer; 2010; 47(1):35-9. PubMed ID: 20071788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.
    Amara S; Dezube BJ; Cooley TP; Pantanowitz L; Aboulafia DM
    Clin Infect Dis; 2006 Nov; 43(9):1198-205. PubMed ID: 17029142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome.
    Tedeschi R; Bortolin MT; Bidoli E; Zanussi S; Pratesi C; Vaccher E; Tirelli U; De Paoli P
    J Clin Virol; 2012 Apr; 53(4):297-301. PubMed ID: 22244256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral T-cell lymphoma in HIV-infected patients: a study of 17 cases in the combination antiretroviral therapy era.
    Gilardin L; Copie-Bergman C; Galicier L; Meignin V; Brière J; Timsit JF; Bouchaud O; Gaulard P; Oksenhendler E; Gérard L
    Br J Haematol; 2013 Jun; 161(6):843-51. PubMed ID: 23593987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
    Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
    Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.